Trial Profile
Phase II Study of Single-agent Pazopanib (Votrient) for Patients With Relapsed or Refractory Germ-cell Tumors (GCT).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Germ cell cancer
- Focus Therapeutic Use
- Acronyms Pazotest-01
- 05 Apr 2017 Results assessing safety and efficacy, published in the Annals of Oncology
- 18 Feb 2017 Status changed from active, no longer recruiting to completed.
- 18 Feb 2017 Final results presented at the 2017 Genitourinary Cancers Symposium